Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery

被引:150
作者
Alabi, Christopher A. [1 ,2 ]
Love, Kevin T. [1 ]
Sahay, Gaurav [1 ]
Yin, Hao [1 ]
Luly, Kathryn M. [5 ]
Langer, Robert [1 ,2 ,3 ,4 ]
Anderson, Daniel G. [1 ,2 ,3 ,4 ]
机构
[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA
[2] MIT, Dept Chem Engn, Cambridge, MA 02139 USA
[3] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[4] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA
[5] Univ Rochester, Dept Biomed Engn, Rochester, NY 14627 USA
基金
美国国家卫生研究院;
关键词
RNAi; thiol-yne; gene silencing; drug carrier; IN-VIVO; TARGETED DELIVERY; RNAI THERAPEUTICS; AMINO LIPIDS; BARRIERS; DESIGN; NANOCARRIERS; CHOLESTEROL; ESCAPE; CELL;
D O I
10.1073/pnas.1306529110
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Nanoparticle-mediated siRNA delivery is a complex process that requires transport across numerous extracellular and intracellular barriers. As such, the development of nanoparticles for efficient delivery would benefit from an understanding of how parameters associated with these barriers relate to the physicochemical properties of nanoparticles. Here, we use a multiparametric approach for the evaluation of lipid nanoparticles (LNPs) to identify relationships between structure, biological function, and biological activity. Our results indicate that evaluation of multiple parameters associated with barriers to delivery such as siRNA entrapment, pK(a), LNP stability, and cell uptake as a collective may serve as a useful prescreening tool for the advancement of LNPs in vivo. This multiparametric approach complements the use of in vitro efficacy results alone for prescreening and improves in vitro-in vivo translation by minimizing false negatives. For the LNPs used in this work, the evaluation of multiple parameters enabled the identification of LNP pK(a) as one of the key determinants of LNP function and activity both in vitro and in vivo. It is anticipated that this type of analysis can aid in the identification of meaningful structure-function-activity relationships, improve the in vitro screening process of nanoparticles before in vivo use, and facilitate the future design of potent nanocarriers.
引用
收藏
页码:12881 / 12886
页数:6
相关论文
共 41 条
[1]
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics [J].
Akinc, Akin ;
Zumbuehl, Andreas ;
Goldberg, Michael ;
Leshchiner, Elizaveta S. ;
Busini, Valentina ;
Hossain, Naushad ;
Bacallado, Sergio A. ;
Nguyen, David N. ;
Fuller, Jason ;
Alvarez, Rene ;
Borodovsky, Anna ;
Borland, Todd ;
Constien, Rainer ;
de Fougerolles, Antonin ;
Dorkin, J. Robert ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
John, Matthias ;
Koteliansky, Victor ;
Manoharan, Muthiah ;
Nechev, Lubomir ;
Qin, June ;
Racie, Timothy ;
Raitcheva, Denitza ;
Rajeev, Kallanthottathil G. ;
Sah, Dinah W. Y. ;
Soutschek, Juergen ;
Toudjarska, Ivanka ;
Vornlocher, Hans-Peter ;
Zimmermann, Tracy S. ;
Langer, Robert ;
Anderson, Daniel G. .
NATURE BIOTECHNOLOGY, 2008, 26 (05) :561-569
[2]
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms [J].
Akinc, Akin ;
Querbes, William ;
De, Soma ;
Qin, June ;
Frank-Kamenetsky, Maria ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Cantley, William L. ;
Dorkin, J. Robert ;
Butler, James S. ;
Qin, LiuLiang ;
Racie, Timothy ;
Sprague, Andrew ;
Fava, Eugenio ;
Zeigerer, Anja ;
Hope, Michael J. ;
Zerial, Marino ;
Sah, Dinah W. Y. ;
Fitzgerald, Kevin ;
Tracy, Mark A. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
de Fougerolles, Antonin ;
Maier, Martin A. .
MOLECULAR THERAPY, 2010, 18 (07) :1357-1364
[3]
Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver [J].
Akinc, Akin ;
Goldberg, Michael ;
Qin, June ;
Dorkin, J. Robert ;
Gamba-Vitalo, Christina ;
Maier, Martin ;
Jayaprakash, K. Narayanannair ;
Jayaraman, Muthusamy ;
Rajeev, Kallanthottathil G. ;
Manoharan, Muthiah ;
Koteliansky, Victor ;
Roehl, Ingo ;
Leshchiner, Elizaveta S. ;
Langer, Robert ;
Anderson, Daniel G. .
MOLECULAR THERAPY, 2009, 17 (05) :872-879
[4]
Attacking the genome: emerging siRNA nanocarriers from concept to clinic [J].
Alabi, Christopher ;
Vegas, Arturo ;
Anderson, Daniel .
CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (04) :427-433
[5]
FRET-Labeled siRNA Probes for Tracking Assembly and Disassembly of siRNA Nanocomplexes [J].
Alabi, Christopher A. ;
Love, Kevin T. ;
Sahay, Gaurav ;
Stutzman, Tina ;
Young, Whitney T. ;
Langer, Robert ;
Anderson, Daniel G. .
ACS NANO, 2012, 6 (07) :6133-6141
[6]
Alnylam Pharmaceuticals, 2012, TRIAL EV SAF TOL PHA
[7]
Alnylam Pharmaceuticals, 2011, TRIAL EV SAF TOL ALN
[8]
MODULATION OF MEMBRANE-FUSION BY ASYMMETRIC TRANSBILAYER DISTRIBUTIONS OF AMINO LIPIDS [J].
BAILEY, AL ;
CULLIS, PR .
BIOCHEMISTRY, 1994, 33 (42) :12573-12580
[9]
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging [J].
Bartlett, DW ;
Davis, ME .
NUCLEIC ACIDS RESEARCH, 2006, 34 (01) :322-333
[10]
A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum [J].
Buyens, Kevin ;
Lucas, Bart ;
Raemdonck, Koen ;
Braeckmans, Kevin ;
Vercammen, Jo ;
Hendrix, Jelle ;
Engelborghs, Yves ;
De Smedt, Stefaan C. ;
Sanders, Niek N. .
JOURNAL OF CONTROLLED RELEASE, 2008, 126 (01) :67-76